Oncopeptides AB stock analysis
Oncopeptides AB (0RN4) Share Price & Analysis
0RN4 Stock Chart & Stats
- Day’s Range
- SEK 1.74 - SEK 1.77
- 52-Week Range
- SEK 1.27 - SEK 5.27
- Previous Close
- SEK 1.79
- Volume
- N/A
- Average Volume (3M)
- 87.27K
- Market Cap
- SEK 772.99M
- Enterprise Value
- SEK 857.23M
- Total Cash (Recent Filing)
- SEK 157.61M
- Total Debt (Recent Filing)
- SEK 135.17M
- Price to Earnings (P/E)
- ―
- Beta
- -0.31
- Next Earnings
- Feb 18, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Commercial Growth And Margins
Strong sales growth combined with an approximately 98% gross margin indicates meaningful commercial traction and attractive product economics. If sustained, this combination can improve operating leverage, support reinvestment, and strengthen the economics of expanding Pepaxti across European markets.
Potential Third-line Label Expansion
A third-line indication would move Pepaxti into an earlier treatment setting, potentially broadening the European patient pool and increasing treatment cycles per patient. Regulatory expansion therefore offers a durable route to higher utilization and a larger commercial opportunity.
Glioblastoma Proof Of Concept
Demonstrated blood-brain barrier penetration addresses a central development challenge in glioblastoma and validates the peptide-drug conjugate approach in humans. This supports further neuro-oncology development and creates a potentially differentiated pipeline opportunity beyond multiple myeloma.
Bears Say
Persistent Cash Burn
Substantial negative operating and free cash flow means the business is not yet self-funding and remains dependent on financing while losses persist. Continued cash consumption can constrain investment flexibility and increase execution pressure before the targeted 2027 positive-cash-flow milestone.
Deep Operating Losses
Very high gross margins have not yet translated into sustainable profitability because operating losses remain far larger than the current revenue base. This gap shows that commercial scale must increase materially or costs must fall before the business can demonstrate durable earnings power.
High Leverage
Debt of roughly 5.4 times equity leaves the balance sheet highly leveraged relative to the company’s still loss-making operations. This reduces capacity to absorb setbacks, limits financial flexibility, and raises dependence on successful commercialization and future capital access.
Oncopeptides AB News
0RN4 FAQ
What was Oncopeptides AB’s price range in the past 12 months?
What is Oncopeptides AB’s market cap?
When is Oncopeptides AB’s upcoming earnings report date?
How were Oncopeptides AB’s earnings last quarter?
Is Oncopeptides AB overvalued?
Does Oncopeptides AB pay dividends?
What is Oncopeptides AB’s EPS estimate?
How many shares outstanding does Oncopeptides AB have?
What happened to Oncopeptides AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Oncopeptides AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Oncopeptides AB
Oncopeptides AB (publ) is a biotechnology firm dedicated to developing medical therapies for cancer, serving markets across the United States, Europe, and worldwide. Its foremost experimental compound, melflufen, is a distinct peptide-drug conjugate engineered to address multiple myeloma that has relapsed or become resistant to prior treatments in adult individuals. Founded in 2000, Oncopeptides AB (publ) conducts its main business from Stockholm, Sweden.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Sofia Heigis
- Employees
- 75
- Website
- www.oncopeptides.com/sv
- Address
- Luntmakargatan 46, Stockholm, AB, 111 37, SE
Oncopeptides AB (0RN4) Earnings & Revenues
0RN4 Earnings Call
Earnings Call SentimentPositive
The call was strongly constructive, with accelerating Pepaxti sales, approximately 98% gross margins, lower operating expenses, improved operating leverage, strengthened financing, a positive CHMP opinion for third-line expansion, and positive initial human glioblastoma data. The main negatives were Q3 seasonality, a flat German market, the still-pending European Commission decision, uncertainty around the glioblastoma development path, additional clinical program costs, and the delayed Japanese partnership process. Highlights significantly outweighed the lowlights.
View all GB:0RN4 earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 5 | 9 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 5 | 0 | 7 |
